Product
FAI Insert
1 clinical trial
3 indications
Indication
UveitisIndication
posteriorIndication
IntermediateClinical trial
A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide (FA) Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the EyeStatus: Terminated, Estimated PCD: 2022-10-17